The biopharma executives appearance in front of the Senate Finance Committee on Feb. 26 produced a surprisingly temperate hearing on drug pricing, but also included a unexpected and potentially worrisome turn when Sen. John Cornyn (R-Texas) recommended the Judiciary Committee pick up a whole separate line of inquiry on drug patents.
Another Congressional review on top of ongoing drug pricing hearings in the House and Senate would be another headache for...







